{"cursor":"9040","size":15,"audio":[],"currentlang":"en","article":"\n{{Drugbox\n| Verifiedfields = changed verifiedrevid = 458274054 image = Ibritumomab\n| tiuxetan structure.svg\n\n\n| type = mab mab_type = mab source = o target = CD20\n\n\n| tradename = Zevalin licence_US = Ibritumomab Drugs.com = pregnancy_AU =  pregnancy_US = \n| legal_AU =  legal_UK =  legal_US = Rx-only routes_of_administration = intravenous\n\n\n| ChemSpiderID_Ref = ChemSpiderID = NA CAS_number_Ref = CAS_number = 174722-31-7\n| ATC_prefix = V10 ATC_suffix = XX02 ATC_supplemental = ( 90 Y)\n| DrugBank_Ref = DrugBank = DB00078 UNII_Ref = UNII = 4Q52C550XK ChEMBL_Ref =\n| ChEMBL = 1201606\n\n }} 'Ibritumomab tiuxetan', sold under the trade name\n'Zevalin', is a monoclonal antibody radioimmunotherapy treatment for relapsed or\nrefractory, low grade or transformed B cell non-Hodgkin's lymphoma, a\nlymphoproliferative disorder and thus affects the lymphatic system. The drug\nuses the monoclonal mouse IgG1 antibody ibritumomab (pronounced as ) [http://body.aol.com/drugs/ibritumomab Ibritumomab:\nPronunciation] in conjunction with the chelator tiuxetan, to which a\nradioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a\nmodified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl\nand a methyl group. {{Cite journal\n| doi = 10.1038/nrd1413 issn = 1474-1776 volume = 3 issue = 6 pages = 488â499\n| last = Milenic first = Diane E. coauthors = Brady, Erik D.; Brechbiel, Martin\n| W. title = Antibody-targeted radiation cancer therapy journal = Nat Rev Drug\n| Discov accessdate = 2009-04-17 date = 2004-06 pmid = 15173838\n}} [http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf WHO Drug\nInformation]\n","linknr":478,"url":"Ibritumomab_tiuxetan","recorded":1364151366,"links":["/w/index.php?title=Ibritumomab_tiuxetan&action=edit","/w/index.php?title=Ibritumomab_tiuxetan&action=edit","//en.wikipedia.org/apple-touch-icon.png","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","#mw-head","#p-search","/wiki/File:Question_book-new.svg","//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","/wiki/Wikipedia:Verifiability","/wiki/Wikipedia:No_original_research#Primary.2C_secondary_and_tertiary_sources","/wiki/Wikipedia:No_original_research#Primary.2C_secondary_and_tertiary_sources","/wiki/Nomenclature_of_monoclonal_antibodies","/wiki/File:Ibritumomab_tiuxetan_structure.svg","//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ibritumomab_tiuxetan_structure.svg/220px-Ibritumomab_tiuxetan_structure.svg.png","/wiki/Monoclonal_antibody#Applications","/wiki/File:Engineered_monoclonal_antibodies.svg","/wiki/Monoclonal_antibody#Production","/wiki/Mouse","/wiki/Antigen","/wiki/CD20","/wiki/Trade_name","/wiki/American_Society_of_Health-System_Pharmacists","/wiki/Drugs.com","http://www.drugs.com/monograph/ibritumomab_tiuxetan.html","/wiki/Regulation_of_therapeutic_goods","/wiki/U.S._Food_and_Drug_Administration","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Ibritumomab&SearchType=BasicSearch","/wiki/Pregnancy_category","/wiki/Regulation_of_therapeutic_goods","/wiki/Prescription_drug","/wiki/United_States","/wiki/Route_of_administration","/wiki/Intravenous","/wiki/CAS_registry_number","http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=174722-31-7&rn=1","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/Anatomical_Therapeutic_Chemical_Classification_System","/wiki/ATC_code_V10","http://www.whocc.no/atc_ddd_index/?code=V10XX02","/wiki/Yttrium-90","/wiki/DrugBank","http://www.drugbank.ca/drugs/DB00078","/wiki/Unique_Ingredient_Identifier","http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4Q52C550XK","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/ChEMBL","https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201606","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/Chemical_formula","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation","//en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458274054&page2=Ibritumomab+tiuxetan","/wiki/Monoclonal_antibody_therapy","/wiki/Radioimmunotherapy","/wiki/B_cell","/wiki/Non-Hodgkin%27s_lymphoma","/wiki/Lymphoproliferative_disorder","/wiki/Lymphatic_system","/wiki/IgG","/wiki/Antibody","#cite_note-1","/wiki/Chelator","/wiki/Yttrium-90","/wiki/Indium-111","/wiki/DTPA","#cite_note-2","#cite_note-3","#Mechanism_of_action","#Administration","#Efficacy","#History","#Costs","#See_also","#External_links","#References","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=1","/wiki/CD20","/wiki/Antigen","/wiki/B_cell","/wiki/Isotope","/wiki/Beta_radiation","/wiki/Antibody-dependent_cell-mediated_cytotoxicity","/wiki/Cytotoxicity","/wiki/Apoptosis","/wiki/Lymphoid","/wiki/Stem_cell","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=2","/wiki/Cytopenia","/wiki/HAMA","/wiki/Rituxan","/wiki/Milli-","/wiki/Curie","/wiki/Mega-","/wiki/Becquerel","#cite_note-4","/wiki/Intravenous_infusion","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=3","/wiki/Clinical_trial","#cite_note-5","#cite_note-6","/wiki/Mantle_cell_lymphoma","#cite_note-7","#cite_note-8","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=4","/wiki/Biogen_Idec","/wiki/Food_and_Drug_Administration","/w/index.php?title=Cell_Therapeutics_Inc&action=edit&redlink=1","#cite_note-9","/wiki/Bayer_Schering_Pharma","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=5","/wiki/Wikipedia:Citation_needed","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=6","/wiki/Tositumomab","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=7","http://www.zevalin.com/","http://www.spectrumpharm.com/","/w/index.php?title=Ibritumomab_tiuxetan&action=edit&section=8","#cite_ref-1","http://body.aol.com/drugs/ibritumomab","#cite_ref-2","/wiki/Digital_object_identifier","http://dx.doi.org/10.1038%2Fnrd1413","/wiki/International_Standard_Serial_Number","//www.worldcat.org/issn/1474-1776","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15173838","#cite_ref-3","http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf","#cite_ref-4","http://www.zevalin.com/us-healthcare-professionals/wp-content/uploads/2012/02/Administration-Facility-Enrollment-Form.pdf","#cite_ref-5","http://www.zevalin.com/us-healthcare-professionals/relapsed-refractory-efficacy-safety/","#cite_ref-6","http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=395156","#cite_ref-7","http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_1029","/wiki/Wikipedia:Link_rot","#cite_ref-8","http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=395048","#cite_ref-9","http://news.yahoo.com/s/ap/20070816/ap_on_sc/cell_therapeutics","/wiki/Wikipedia:Link_rot","/wiki/Template:Monoclonals_for_tumors","/wiki/Template_talk:Monoclonals_for_tumors","//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_tumors&action=edit","/wiki/Monoclonal_antibodies","/wiki/Tumor","/wiki/Adecatumumab","/wiki/Cixutumumab","/wiki/Conatumumab","/wiki/Daratumumab","/wiki/Drozitumab","/wiki/Duligotumab","/wiki/Dusigitumab","/wiki/Figitumumab","/wiki/Ganitumab","/wiki/Glembatumumab_vedotin","/wiki/Intetumumab","/wiki/Iratumumab","/wiki/Lexatumumab","/wiki/Lucatumumab","/wiki/Mapatumumab","/wiki/Narnatumab","/wiki/Necitumumab","/wiki/Ofatumumab","/wiki/Olaratumab","/wiki/Panitumumab","/wiki/Patritumab","/wiki/Pritumumab","/wiki/Radretumab","/wiki/Rilotumumab","/wiki/Robatumumab","/wiki/Teprotumumab","/wiki/Tovetumab","/wiki/Vantictumab","/wiki/Technetium_(99mTc)_votumumab","/wiki/Zalutumumab","/wiki/Melanoma","/wiki/Flanvotumab","/wiki/Indium_(111In)_altumomab_pentetate","/wiki/Anatumomab_mafenatox","/wiki/Technetium_(99mTc)_arcitumomab","/wiki/Bectumomab","/wiki/Blinatumomab","/wiki/Iodine_(125I)_CC49","/wiki/Detumomab","/wiki/Minretumomab","/wiki/Mitumomab","/wiki/Moxetumomab_pasudotox","/wiki/Naptumomab_estafenatox","/wiki/Technetium_(99mTc)_nofetumomab_merpentan","/wiki/Pemtumomab","/wiki/Technetium_(99mTc)_pintumomab","/wiki/Racotumomab","/wiki/Indium_(111In)_satumomab_pendetide","/wiki/Solitomab","/wiki/Taplitumomab_paptox","/wiki/Tenatumomab","/wiki/Tositumomab","/wiki/3F8","/wiki/Ovarian_tumor","/wiki/Abagovomab","/wiki/Indium_(111In)_igovomab","/wiki/Oregovomab","/wiki/Indium_(111In)_capromab_pendetide","/wiki/Edrecolomab","/wiki/Nacolomab_tafenatox","/wiki/Chimeric_antibody","/wiki/Amatuximab","/wiki/Bavituximab","/wiki/Brentuximab_vedotin","/wiki/Cetuximab","/wiki/Ensituximab","/wiki/Futuximab","/wiki/Girentuximab","/wiki/Indatuximab_ravtansine","/wiki/Margetuximab","/wiki/Rituximab","/wiki/Siltuximab","/wiki/Ublituximab","/wiki/Melanoma","/wiki/Ecromeximab","/wiki/Humanized_antibody","/wiki/Afutuzumab","/wiki/Alemtuzumab","/wiki/Bevacizumab","/wiki/Bivatuzumab_mertansine","/wiki/Cantuzumab_mertansine","/wiki/Cantuzumab_ravtansine","/wiki/Citatuzumab_bogatox","/wiki/Yttrium_(90Y)_clivatuzumab_tetraxetan","/wiki/Dacetuzumab","/wiki/Dalotuzumab","/wiki/Elotuzumab","/wiki/Etaracizumab","/wiki/Farletuzumab","/wiki/Ficlatuzumab","/wiki/Gemtuzumab_ozogamicin","/wiki/Imgatuzumab","/wiki/Inotuzumab_ozogamicin","/wiki/Labetuzumab","/wiki/Lintuzumab","/wiki/Lorvotuzumab_mertansine","/wiki/Matuzumab","/wiki/Milatuzumab","/wiki/Nimotuzumab","/wiki/Ocaratuzumab","/wiki/Onartuzumab","/wiki/Oportuzumab_monatox","/wiki/Parsatuzumab","/wiki/Pertuzumab","/wiki/Sibrotuzumab","/wiki/Simtuzumab","/wiki/Yttrium_(90Y)_tacatuzumab_tetraxetan","/wiki/Tigatuzumab","/wiki/Trastuzumab","/wiki/Tucotuzumab_celmoleukin","/wiki/Veltuzumab","/wiki/Vorsetuzumab_mafodotin","/wiki/Trifunctional_antibody","/wiki/Catumaxomab","/wiki/Ertumaxomab","/wiki/List_of_World_Health_Organization_Essential_Medicines","/wiki/List_of_withdrawn_drugs","/wiki/Clinical_trial","/wiki/Clinical_trial#Phase_III","/wiki/Clinical_trial#Phase_II","/wiki/Template:Radiopharmaceuticals","/wiki/Template_talk:Radiopharmaceuticals","//en.wikipedia.org/w/index.php?title=Template:Radiopharmaceuticals&action=edit","/wiki/Radiopharmacology","/wiki/ATC_code_V10","/wiki/Palliation","/wiki/Samarium-153","/wiki/Samarium_(153Sm)_lexidronam","/wiki/Strontium-89","/wiki/Adrenergic","/wiki/Iodine-131","/wiki/Iobenguane","/wiki/CD20","/wiki/Monoclonal_antibody","/wiki/Yttrium-90","/wiki/Iodine-131","/wiki/Tositumomab","/wiki/Radionuclide","/wiki/Beta_particle","/wiki/Electron","/wiki/Samarium-153","/wiki/Yttrium-90","/wiki/Phosphorus-32","/wiki/Iodine-131","/wiki/Strontium-89","/wiki/Dysprosium-165","/wiki/Erbium-169","/wiki/Rhenium-186","/wiki/Gold-198","/wiki/Template:Extracellular_chemotherapeutic_agents","/wiki/Template_talk:Extracellular_chemotherapeutic_agents","//en.wikipedia.org/w/index.php?title=Template:Extracellular_chemotherapeutic_agents&action=edit","/wiki/Targeted_therapy","/wiki/Chemotherapy_(oncology)","/wiki/Antineoplastic","/wiki/ATC_code_L01","/wiki/Cancer_immunotherapy","/wiki/Monoclonal_antibody_therapy","/wiki/Receptor_tyrosine_kinase","/wiki/ErbB","/wiki/Epidermal_growth_factor_receptor","/wiki/Cetuximab","/wiki/Panitumumab","/wiki/HER2/neu","/wiki/Trastuzumab","/wiki/Trastuzumab_emtansine","/wiki/EpCAM","/wiki/Catumaxomab","/wiki/Edrecolomab","/wiki/Vascular_endothelial_growth_factor_A","/wiki/Bevacizumab","/wiki/Leukemia","/wiki/Lymphoma","/wiki/Lymphatic_system","/wiki/CD20","/wiki/Ofatumumab","/wiki/Rituximab","/wiki/Tositumomab","/wiki/CD30","/wiki/Brentuximab_vedotin","/wiki/CD52","/wiki/Alemtuzumab","/wiki/Myeloid","/wiki/CD33","/wiki/Gemtuzumab_ozogamicin","/wiki/Tyrosine-kinase_inhibitor","/wiki/Receptor_tyrosine_kinase","/wiki/ErbB","/wiki/Epidermal_growth_factor_receptor","/wiki/Erlotinib","/wiki/Gefitinib","/wiki/Vandetanib","/wiki/HER2/neu","/wiki/Afatinib","/wiki/Lapatinib","/wiki/Neratinib","/wiki/RTK_class_III","/wiki/CD117","/wiki/Platelet-derived_growth_factor_receptor","/wiki/Axitinib","/wiki/Masitinib","/wiki/Pazopanib","/wiki/Sunitinib","/wiki/Sorafenib","/wiki/Toceranib","/wiki/CD135","/wiki/Lestaurtinib","/wiki/VEGF_receptors","/wiki/Axitinib","/wiki/Cediranib","/wiki/Pazopanib","/wiki/Regorafenib","/wiki/Semaxanib","/wiki/Sorafenib","/wiki/Sunitinib","/wiki/Toceranib","/wiki/Vandetanib","/wiki/Non-receptor_tyrosine_kinase","/wiki/Bcr-abl_fusion_protein","/wiki/Imatinib","/wiki/Dasatinib","/wiki/Nilotinib","/wiki/Ponatinib","/wiki/Src_(gene)","/wiki/Bosutinib","/wiki/Janus_kinase","/wiki/Lestaurtinib","/wiki/Ruxolitinib","/wiki/EML4","/wiki/Anaplastic_lymphoma_kinase","/wiki/Crizotinib","/wiki/Vandetanib","/wiki/Cabozantinib","/wiki/Fusion_protein","/wiki/Vascular_endothelial_growth_factor","/wiki/Aflibercept","/wiki/Proapoptotic","/wiki/ANXA2","/wiki/Prohibitin","/wiki/Adipotide","/wiki/Exotoxin","/wiki/Interleukin_2","/wiki/Denileukin_diftitox","/wiki/MTOR_inhibitor","/wiki/Everolimus","/wiki/Temsirolimus","/wiki/Template:Medicine_navs","/wiki/Neoplasm","/wiki/Template:Tumor_suppressor_genes_and_oncogenes","/wiki/Template:Tumor_markers","/wiki/Template:Tumors","/wiki/Template:Eponymous_medical_signs_for_oncology","/wiki/Template:Paraneoplastic_syndromes","/wiki/ATC_code_L","/wiki/Template:Intracellular_chemotherapeutic_agents","/wiki/Template:Extracellular_chemotherapeutic_agents","/wiki/Template:Detoxifying_agents_for_antineoplastic_treatment","http://en.wikipedia.org/w/index.php?title=Ibritumomab_tiuxetan&oldid=541707172","/wiki/Help:Categories","/wiki/Category:Monoclonal_antibodies_for_tumors","/wiki/Category:All_articles_with_dead_external_links","/wiki/Category:Articles_with_dead_external_links_from_October_2009","/wiki/Category:Articles_lacking_reliable_references_from_October_2009","/wiki/Category:All_articles_lacking_reliable_references","/wiki/Category:Chemical_compounds_which_do_not_have_a_ChemSpiderID","/wiki/Category:Articles_with_changed_FDA_identifier","/wiki/Category:Articles_with_changed_EBI_identifier","/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields","/wiki/Category:All_articles_with_unsourced_statements","/wiki/Category:Articles_with_unsourced_statements_from_November_2011","/w/index.php?title=Special:UserLogin&returnto=Ibritumomab+tiuxetan&type=signup","/w/index.php?title=Special:UserLogin&returnto=Ibritumomab+tiuxetan","/wiki/Ibritumomab_tiuxetan","/wiki/Talk:Ibritumomab_tiuxetan","#","/wiki/Ibritumomab_tiuxetan","/w/index.php?title=Ibritumomab_tiuxetan&action=edit","/w/index.php?title=Ibritumomab_tiuxetan&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","//donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Ibritumomab_tiuxetan","/wiki/Special:RecentChangesLinked/Ibritumomab_tiuxetan","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Ibritumomab_tiuxetan&oldid=541707172","/w/index.php?title=Ibritumomab_tiuxetan&action=info","/w/index.php?title=Special:Cite&page=Ibritumomab_tiuxetan&id=541707172","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Ibritumomab+tiuxetan","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Ibritumomab+tiuxetan&oldid=541707172&writer=rl","/w/index.php?title=Ibritumomab_tiuxetan&printable=yes","//de.wikipedia.org/wiki/Ibritumomab-Tiuxetan","//it.wikipedia.org/wiki/Ibritumomab_tiuxetan","//ja.wikipedia.org/wiki/%E3%82%A4%E3%83%96%E3%83%AA%E3%83%84%E3%83%A2%E3%83%9E%E3%83%96_%E3%83%81%E3%82%A6%E3%82%AD%E3%82%BB%E3%82%BF%E3%83%B3","//www.wikidata.org/wiki/Special:ItemByTitle/enwiki/Ibritumomab tiuxetan","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//www.wikimediafoundation.org/","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","http://en.m.wikipedia.org/wiki/Ibritumomab_tiuxetan","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=skins.vector&only=scripts&skin=vector&*","/w/index.php?title=MediaWiki:Gadget-ReferenceTooltips.js&action=raw&ctype=text/javascript&508635914","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":[],"pdf":["http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf","http://www.zevalin.com/us-healthcare-professionals/wp-content/uploads/2012/02/Administration-Facility-Enrollment-Form.pdf"],"categories":["Monoclonal antibodies for tumors"],"headings":["Mechanism of action","Administration","Efficacy","History","Costs","See also","External links","References"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ibritumomab_tiuxetan_structure.svg/220px-Ibritumomab_tiuxetan_structure.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[],"members":[],"related":["CD20","Intravenous","Yttrium-90","Monoclonal_antibody_therapy","Radioimmunotherapy","B_cell","Non-Hodgkin's_lymphoma","Lymphoproliferative_disorder","Lymphatic_system","IgG","Antibody","Chelator","Yttrium-90","Indium-111","DTPA","CD20","Antigen","B_cell","Isotope","Beta_radiation","Antibody-dependent_cell-mediated_cytotoxicity","Cytotoxicity","Apoptosis","Lymphoid","Stem_cell","Cytopenia","HAMA","Rituxan","Milli-","Curie","Mega-","Becquerel","Intravenous_infusion","Clinical_trial","Mantle_cell_lymphoma","Biogen_Idec","Food_and_Drug_Administration","Cell_Therapeutics_Inc","Bayer_Schering_Pharma","Tositumomab"]}